Annual Operating Profit
-$103.71 M
+$44.73 M+30.13%
31 December 2023
Summary:
BioCryst Pharmaceuticals annual operaing income is currently -$103.71 million, with the most recent change of +$44.73 million (+30.13%) on 31 December 2023. During the last 3 years, it has risen by +$74.01 million (+41.64%). BCRX annual operating profit is now -1980.21% below its all-time high of -$4.99 million, reached on 31 December 2001.BCRX Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
$7.69 M
-$1.07 M-12.20%
30 September 2024
Summary:
BioCryst Pharmaceuticals quarterly operating income is currently $7.69 million, with the most recent change of -$1.07 million (-12.20%) on 30 September 2024. Over the past year, it has increased by +$50.36 million (+118.03%). BCRX quarterly operating profit is now -49.01% below its all-time high of $15.09 million, reached on 31 December 2009.BCRX Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
-$40.70 M
+$19.61 M+32.52%
30 September 2024
Summary:
BioCryst Pharmaceuticals TTM operating income is currently -$40.70 million, with the most recent change of +$19.61 million (+32.52%) on 30 September 2024. Over the past year, it has increased by +$63.00 million (+60.75%). BCRX TTM operating profit is now -2613.67% below its all-time high of -$1.50 million, reached on 31 March 1994.BCRX TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BCRX Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +118.0% | +60.8% |
| 3 y3 years | +41.6% | +114.7% | +77.1% |
| 5 y5 years | -4.3% | +7156.9% | +59.1% |
BCRX Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +41.6% | -12.2% | +114.7% | at high | +77.6% |
| 5 y | 5 years | -10.1% | +41.6% | -12.2% | +114.7% | at high | +78.0% |
| alltime | all time | -1980.2% | +41.6% | -49.0% | +114.7% | -2613.7% | +78.0% |
BioCryst Pharmaceuticals Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $7.69 M(-12.2%) | -$40.70 M(-32.5%) |
| June 2024 | - | $8.76 M(-160.5%) | -$60.32 M(-32.8%) |
| Mar 2024 | - | -$14.49 M(-66.0%) | -$89.78 M(-13.4%) |
| Dec 2023 | -$103.71 M(-30.1%) | -$42.67 M(+257.9%) | -$103.71 M(-3.4%) |
| Sept 2023 | - | -$11.92 M(-42.4%) | -$107.35 M(-4.9%) |
| June 2023 | - | -$20.70 M(-27.1%) | -$112.87 M(-11.0%) |
| Mar 2023 | - | -$28.41 M(-38.6%) | -$126.89 M(-14.5%) |
| Dec 2022 | -$148.44 M(-16.5%) | -$46.31 M(+165.5%) | -$148.44 M(-3.8%) |
| Sept 2022 | - | -$17.45 M(-49.8%) | -$154.30 M(-15.0%) |
| June 2022 | - | -$34.72 M(-30.5%) | -$181.44 M(+2.9%) |
| Mar 2022 | - | -$49.96 M(-4.3%) | -$176.30 M(-0.8%) |
| Dec 2021 | -$177.72 M(+1.7%) | -$52.18 M(+17.0%) | -$177.72 M(-0.1%) |
| Sept 2021 | - | -$44.58 M(+50.7%) | -$177.95 M(+1.0%) |
| June 2021 | - | -$29.58 M(-42.4%) | -$176.23 M(-4.8%) |
| Mar 2021 | - | -$51.38 M(-2.0%) | -$185.16 M(+6.0%) |
| Dec 2020 | -$174.76 M(+75.7%) | -$52.41 M(+22.3%) | -$174.76 M(+42.7%) |
| Sept 2020 | - | -$42.86 M(+11.3%) | -$122.46 M(+6.8%) |
| June 2020 | - | -$38.51 M(-6.0%) | -$114.69 M(+3.2%) |
| Mar 2020 | - | -$40.98 M(>+9900.0%) | -$111.10 M(+11.7%) |
| Dec 2019 | -$99.45 M(+5.6%) | -$109.00 K(-99.7%) | -$99.45 M(-20.2%) |
| Sept 2019 | - | -$35.10 M(+0.5%) | -$124.61 M(+5.6%) |
| June 2019 | - | -$34.92 M(+19.1%) | -$118.00 M(+16.4%) |
| Mar 2019 | - | -$29.33 M(+16.1%) | -$101.34 M(+7.6%) |
| Dec 2018 | -$94.22 M(+64.1%) | -$25.26 M(-11.3%) | -$94.22 M(+8.5%) |
| Sept 2018 | - | -$28.49 M(+56.1%) | -$86.82 M(+21.1%) |
| June 2018 | - | -$18.25 M(-17.8%) | -$71.67 M(+4.0%) |
| Mar 2018 | - | -$22.21 M(+24.4%) | -$68.94 M(+20.1%) |
| Dec 2017 | -$57.41 M(+18.1%) | -$17.86 M(+33.8%) | -$57.41 M(+20.3%) |
| Sept 2017 | - | -$13.35 M(-14.0%) | -$47.74 M(+9.4%) |
| June 2017 | - | -$15.52 M(+45.2%) | -$43.63 M(+8.4%) |
| Mar 2017 | - | -$10.69 M(+30.5%) | -$40.24 M(-17.2%) |
| Dec 2016 | -$48.61 M(+23.2%) | -$8.19 M(-11.4%) | -$48.61 M(-15.6%) |
| Sept 2016 | - | -$9.24 M(-23.8%) | -$57.61 M(-6.4%) |
| June 2016 | - | -$12.13 M(-36.3%) | -$61.53 M(+39.7%) |
| Mar 2016 | - | -$19.05 M(+10.8%) | -$44.06 M(+11.7%) |
| Dec 2015 | -$39.44 M(-13.8%) | -$17.19 M(+30.6%) | -$39.44 M(+5.4%) |
| Sept 2015 | - | -$13.16 M(-346.4%) | -$37.41 M(+4.3%) |
| June 2015 | - | $5.34 M(-137.0%) | -$35.85 M(-32.1%) |
| Mar 2015 | - | -$14.43 M(-4.8%) | -$52.81 M(+15.4%) |
| Dec 2014 | -$45.77 M(+49.0%) | -$15.16 M(+30.5%) | -$45.77 M(+23.9%) |
| Sept 2014 | - | -$11.61 M(-0.1%) | -$36.95 M(+14.5%) |
| June 2014 | - | -$11.62 M(+57.3%) | -$32.26 M(-1.6%) |
| Mar 2014 | - | -$7.39 M(+16.6%) | -$32.79 M(+6.7%) |
| Dec 2013 | -$30.72 M(-4.4%) | -$6.33 M(-8.5%) | -$30.72 M(-7.8%) |
| Sept 2013 | - | -$6.92 M(-43.0%) | -$33.32 M(-3.2%) |
| June 2013 | - | -$12.14 M(+128.4%) | -$34.41 M(+6.1%) |
| Mar 2013 | - | -$5.32 M(-40.5%) | -$32.44 M(+1.0%) |
| Dec 2012 | -$32.13 M(-35.2%) | -$8.94 M(+11.5%) | -$32.13 M(-6.2%) |
| Sept 2012 | - | -$8.02 M(-21.2%) | -$34.23 M(-12.3%) |
| June 2012 | - | -$10.18 M(+103.5%) | -$39.02 M(-9.4%) |
| Mar 2012 | - | -$5.00 M(-54.7%) | -$43.09 M(-13.1%) |
| Dec 2011 | -$49.59 M(+48.8%) | -$11.04 M(-13.8%) | -$49.59 M(+3.7%) |
| Sept 2011 | - | -$12.80 M(-10.1%) | -$47.82 M(+3.9%) |
| June 2011 | - | -$14.24 M(+23.9%) | -$46.01 M(+9.3%) |
| Mar 2011 | - | -$11.50 M(+24.0%) | -$42.09 M(+26.3%) |
| Dec 2010 | -$33.32 M(+142.6%) | -$9.27 M(-15.6%) | -$33.32 M(+271.8%) |
| Sept 2010 | - | -$10.99 M(+6.4%) | -$8.96 M(+3.4%) |
| June 2010 | - | -$10.33 M(+278.5%) | -$8.67 M(+22.5%) |
| Mar 2010 | - | -$2.73 M(-118.1%) | -$7.08 M(-48.5%) |
| Dec 2009 | -$13.74 M | $15.09 M(-241.0%) | -$13.74 M(-27.8%) |
| Sept 2009 | - | -$10.70 M(+22.4%) | -$19.02 M(+6.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$8.74 M(-6.9%) | -$17.89 M(-20.6%) |
| Mar 2009 | - | -$9.39 M(-195.7%) | -$22.54 M(-17.0%) |
| Dec 2008 | -$27.16 M(-15.8%) | $9.80 M(-202.4%) | -$27.16 M(-32.8%) |
| Sept 2008 | - | -$9.57 M(-28.5%) | -$40.40 M(-5.4%) |
| June 2008 | - | -$13.38 M(-4.5%) | -$42.69 M(+15.7%) |
| Mar 2008 | - | -$14.02 M(+308.9%) | -$36.89 M(+54.9%) |
| Dec 2007 | -$32.28 M(-31.3%) | -$3.43 M(-71.1%) | -$23.81 M(-23.5%) |
| Sept 2007 | - | -$11.86 M(+56.4%) | -$31.12 M(-12.9%) |
| June 2007 | - | -$7.58 M(+705.9%) | -$35.72 M(-8.8%) |
| Mar 2007 | - | -$940.80 K(-91.2%) | -$39.15 M(-16.7%) |
| Dec 2006 | -$46.98 M(+72.9%) | -$10.74 M(-34.8%) | -$46.98 M(+7.4%) |
| Sept 2006 | - | -$16.46 M(+49.4%) | -$43.73 M(+24.2%) |
| June 2006 | - | -$11.02 M(+25.7%) | -$35.20 M(+16.9%) |
| Mar 2006 | - | -$8.77 M(+17.1%) | -$30.11 M(+10.8%) |
| Dec 2005 | -$27.18 M(+24.9%) | -$7.49 M(-5.5%) | -$27.18 M(+8.2%) |
| Sept 2005 | - | -$7.93 M(+33.6%) | -$25.12 M(+10.9%) |
| June 2005 | - | -$5.93 M(+1.7%) | -$22.64 M(+3.2%) |
| Mar 2005 | - | -$5.83 M(+7.4%) | -$21.94 M(+0.9%) |
| Dec 2004 | -$21.75 M(+59.0%) | -$5.43 M(-0.4%) | -$21.75 M(+5.8%) |
| Sept 2004 | - | -$5.45 M(+4.2%) | -$20.55 M(+11.0%) |
| June 2004 | - | -$5.23 M(-7.3%) | -$18.51 M(+12.0%) |
| Mar 2004 | - | -$5.64 M(+33.4%) | -$16.53 M(+20.9%) |
| Dec 2003 | -$13.68 M(-26.9%) | -$4.23 M(+24.1%) | -$13.68 M(-4.6%) |
| Sept 2003 | - | -$3.41 M(+4.8%) | -$14.33 M(-0.0%) |
| June 2003 | - | -$3.25 M(+16.6%) | -$14.34 M(-12.2%) |
| Mar 2003 | - | -$2.79 M(-42.9%) | -$16.34 M(-14.8%) |
| Dec 2002 | -$18.70 M(+275.2%) | -$4.88 M(+43.0%) | -$19.16 M(+13.5%) |
| Sept 2002 | - | -$3.42 M(-34.9%) | -$16.88 M(+24.3%) |
| June 2002 | - | -$5.25 M(-6.6%) | -$13.59 M(+64.0%) |
| Mar 2002 | - | -$5.62 M(+115.6%) | -$8.28 M(+58.3%) |
| Dec 2001 | -$4.99 M(-49.3%) | -$2.60 M(+2088.7%) | -$5.23 M(-7.9%) |
| Sept 2001 | - | -$119.00 K(-316.4%) | -$5.68 M(-24.7%) |
| June 2001 | - | $55.00 K(-102.1%) | -$7.55 M(-24.8%) |
| Mar 2001 | - | -$2.57 M(-16.0%) | -$10.04 M(+1.6%) |
| Dec 2000 | -$9.83 M(+21.4%) | -$3.06 M(+54.0%) | -$9.88 M(+7.1%) |
| Sept 2000 | - | -$1.98 M(-18.5%) | -$9.23 M(-6.2%) |
| June 2000 | - | -$2.43 M(+0.9%) | -$9.85 M(+24.3%) |
| Mar 2000 | - | -$2.41 M(+0.5%) | -$7.92 M(-1.1%) |
| Dec 1999 | -$8.10 M(+35.0%) | -$2.40 M(-7.7%) | -$8.01 M(+8.1%) |
| Sept 1999 | - | -$2.60 M(+411.6%) | -$7.41 M(+207.6%) |
| June 1999 | - | -$508.00 K(-79.7%) | -$2.41 M(-52.8%) |
| Mar 1999 | - | -$2.50 M(+38.9%) | -$5.10 M(-12.1%) |
| Dec 1998 | -$6.00 M(-51.2%) | -$1.80 M(-175.0%) | -$5.80 M(-21.6%) |
| Sept 1998 | - | $2.40 M(-175.0%) | -$7.40 M(-41.3%) |
| June 1998 | - | -$3.20 M(0.0%) | -$12.60 M(+5.9%) |
| Mar 1998 | - | -$3.20 M(-5.9%) | -$11.90 M(-2.5%) |
| Dec 1997 | -$12.30 M(+41.4%) | -$3.40 M(+21.4%) | -$12.20 M(+1.7%) |
| Sept 1997 | - | -$2.80 M(+12.0%) | -$12.00 M(+3.4%) |
| June 1997 | - | -$2.50 M(-28.6%) | -$11.60 M(+11.5%) |
| Mar 1997 | - | -$3.50 M(+9.4%) | -$10.40 M(+18.2%) |
| Dec 1996 | -$8.70 M(-4.4%) | -$3.20 M(+33.3%) | -$8.80 M(+11.4%) |
| Sept 1996 | - | -$2.40 M(+84.6%) | -$7.90 M(+3.9%) |
| June 1996 | - | -$1.30 M(-31.6%) | -$7.60 M(-5.0%) |
| Mar 1996 | - | -$1.90 M(-17.4%) | -$8.00 M(-11.1%) |
| Dec 1995 | -$9.10 M(+33.8%) | -$2.30 M(+9.5%) | -$9.00 M(+4.7%) |
| Sept 1995 | - | -$2.10 M(+23.5%) | -$8.60 M(+4.9%) |
| June 1995 | - | -$1.70 M(-41.4%) | -$8.20 M(-2.4%) |
| Mar 1995 | - | -$2.90 M(+52.6%) | -$8.40 M(+20.0%) |
| Dec 1994 | -$6.80 M | -$1.90 M(+11.8%) | -$7.00 M(+37.3%) |
| Sept 1994 | - | -$1.70 M(-10.5%) | -$5.10 M(+50.0%) |
| June 1994 | - | -$1.90 M(+26.7%) | -$3.40 M(+126.7%) |
| Mar 1994 | - | -$1.50 M | -$1.50 M |
FAQ
- What is BioCryst Pharmaceuticals annual operaing income?
- What is the all time high annual operating profit for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly operating income?
- What is the all time high quarterly operating profit for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals quarterly operating profit year-on-year change?
- What is BioCryst Pharmaceuticals TTM operating income?
- What is the all time high TTM operating profit for BioCryst Pharmaceuticals?
- What is BioCryst Pharmaceuticals TTM operating profit year-on-year change?
What is BioCryst Pharmaceuticals annual operaing income?
The current annual operating profit of BCRX is -$103.71 M
What is the all time high annual operating profit for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high annual operaing income is -$4.99 M
What is BioCryst Pharmaceuticals quarterly operating income?
The current quarterly operating profit of BCRX is $7.69 M
What is the all time high quarterly operating profit for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high quarterly operating income is $15.09 M
What is BioCryst Pharmaceuticals quarterly operating profit year-on-year change?
Over the past year, BCRX quarterly operating income has changed by +$50.36 M (+118.03%)
What is BioCryst Pharmaceuticals TTM operating income?
The current TTM operating profit of BCRX is -$40.70 M
What is the all time high TTM operating profit for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals all-time high TTM operating income is -$1.50 M
What is BioCryst Pharmaceuticals TTM operating profit year-on-year change?
Over the past year, BCRX TTM operating income has changed by +$63.00 M (+60.75%)